Bacterial incidence and drug resistance from pathogens recovered from blood, cerebrospinal and pleural fluids in 2019–2020. Results of the Invifar network
- Published
- Accepted
- Received
- Academic Editor
- Cindy Shuan Ju Teh
- Subject Areas
- Microbiology, Drugs and Devices, Infectious Diseases
- Keywords
- Drug resistance, Blood stream infection, Cerebrospinal infection, Escherichia coli, INVIFAR
- Copyright
- © 2023 Garza-González et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
- Cite this article
- 2023. Bacterial incidence and drug resistance from pathogens recovered from blood, cerebrospinal and pleural fluids in 2019–2020. Results of the Invifar network. PeerJ 11:e14411 https://doi.org/10.7717/peerj.14411
Abstract
Background
Antimicrobial resistance is a global concern. Analysis of sterile fluids is essential because microorganisms are defined as significant in most cases. Blood, cerebrospinal, and pleural fluids are frequently received in the microbiology lab because they are associated with considerable rates of morbi-mortality. Knowledge of epidemiology in these samples is needed to choose proper empirical treatments due to the importance of reducing selection pressure.
Methods
We used retrospective laboratory data of blood, CSF, and pleural fluid collected from patients in Mexico between 2019 and 2020. Each laboratory identified the strains and tested susceptibility using its routine methods. For Streptococcus pneumoniae, a comparative analysis was performed with data from the broth microdilution method.
Results
Forty-five centers participated in the study, with 30,746 clinical isolates from blood, 2,429 from pleural fluid, and 2,275 from CSF. For blood and CSF, Staphylococcus epidermidis was the most frequent. For blood, among gram negatives, the most frequent was Escherichia coli. Among Enterobacterales, 9.8% of K. pneumoniae were carbapenem-resistant. For S. pneumoniae, similar resistance percentages were observed for levofloxacin, cefotaxime, and vancomycin. For CSF, the most frequent gram-negative was E. coli. In Acinetobacter baumannii, carbapenem resistance was 71.4%. The most frequent species detected for pleural fluid was E. coli; in A. baumannii, carbapenem resistance was 96.3%.
Conclusion
Gram-negative bacteria, with E. coli most prevalent, are frequently recovered from CSF, blood, and pleural fluid. In S. pneumoniae, the routine, conventional methods showed good agreement in detecting resistance percentages for erythromycin, levofloxacin, and vancomycin.
Introduction
Bacterial species are developing resistance to many antibiotics (Prestinaci, Pezzotti & Pantosti, 2015; Paphitou, 2013; Karam & Heffner, 2000; Laxminarayan et al., 2013; Pogue et al., 2015). To control the dissemination of these organisms, it is necessary to monitor the antimicrobial susceptibility of the microorganisms most frequently detected in hospitals (Roca et al., 2015). The analysis of sterile fluids is essential because potential pathogens are considered significant in most cases (Opota et al., 2015). Blood, cerebrospinal fluid (CSF), and pleural fluid are sterile fluids frequently received in the microbiology laboratory for culture in suspected infections. These infections are associated with considerable morbidity and mortality (Proulx et al., 2005).
Regarding blood cultures, mortality associated with bloodstream infections is directly related to the delay in administering the first adequate antimicrobial agent (Ferrer et al., 2014). Empirical antimicrobial infectious treatments are chosen based on clinical and epidemiological data (Paul et al., 2010).
Bacterial meningitis occurs primarily in childhood and is associated with a high mortality rate and potentially severe morbidity. Antibiotic resistance may limit the effectiveness of treatment (Kim, 2010; Briand et al., 2016). Thus, early diagnosis and appropriate antibiotic therapy are needed to avoid further complications.
Pleural infections are a significant cause of morbidity or death, and their incidence continues to rise (Farjah et al., 2007). Current guidelines recommend pleural fluid microbiological studies to direct antibiotic treatment (Light, 1999). Mortality has been found to increase as much as 40% when gram-negative bacteria, Staphylococcus aureus, or a mixed aerobic infection are detected (Maskell et al., 2006). Thus, reliable identification of these groups would allow the targeting of early aggressive therapy, and calculations of resistance percentages may help in the use of adequate empirical treatments.
It is necessary to define local and national resistance rates for various pathogens in the blood and other sterile body fluids to provide baseline data that can serve as an essential reference for monitoring resistance and empirical therapy changes. Thus, the present study investigated the cumulative incidence and antimicrobial susceptibility patterns from pathogens recovered from sterile fluids.
Material and Methods
Ethics statement
This study was performed in compliance with the requirements of the Research and Biosafety Ethics Committee of the Antiguo Hospital Civil de Guadalajara “Fray Antonio Alcalde,” Jalisco, Mexico, which approved this study with reference number 129/17. The ethics committee waived informed consent because no intervention was involved, and no patient-identifying information was included. All institutions agreed to participate.
Participating centers, data collection, and analysis
The centers from the Network for the Research and Surveillance of Drug Resistance (Red Temática de Investigación y Vigilancia de la Farmacorresistencia, INVIFAR in Spanish) were invited to participate in the study. The INVIFAR network was created in March 2018 to contribute to improving the surveillance and control of drug resistance in Mexico and the performance of the network’s laboratories, comprised of laboratories, hospitals, research centers, and universities in Mexico. Participating centers provided retrospective aggregated laboratory data of blood, CSF, and pleural liquid collected from January 1, 2019, to December 31, 2020.
Each laboratory identified the strains and tested their susceptibilities using routine, conventional methods, including commercial microdilution systems (VITEK 2, Biomérieux; Phoenix Automated Microbiology System, Becton, Dickinson; MicroScan WalkAway, Siemens Healthcare Diagnostics; and Sensititre, TREK Diagnostic Systems Inc.) or the disk diffusion susceptibility method.
All databases were deposited into the WHONET 5.6 platform and converted to the WHONET format using the BacLink 2 tool. Only one strain per patient was included. The distribution of antimicrobial resistance was included for clinical isolates recovered from blood, CSF, and pleural liquid. Clinical and Laboratory Standards Institute (CLSI) criteria were used to score the results (CLSI, 2020). Databases included type of body fluid, isolated bacterial species, antibiotic tested, and susceptibility test results.
Susceptibility testing for Streptococcus pneumoniae
For S. pneumoniae, a comparative analysis was conducted between results observed for routine, conventional methods with data from the broth microdilution (BMD) method. Only blood isolates were included in this study. This work was performed with the collaboration of the SIREVA/GIVEBPVac (Grupo Interinstitutional para la Vigilancia de Enfermedades Bacterianas Prevenibles por Vacunación, in Spanish) network. Susceptibility testing was performed by BMD following the guidelines of the CLSI (2020). S. pneumoniae ATCC 49619 was used as a control strain. Cation-adjusted Mueller Hinton broth (Becton, Dickinson, MD, USA), which had lysed horse blood added to a final concentration of 5%, was used as a medium.
Results
Participating centers and included clinical isolates
Forty-five centers participated in the study, contributing 35,450 clinical isolates recovered from sterile fluids, which included 30,746 from blood, 2,429 from pleural fluid, and 2,275 from CSF.
The most frequently detected bacterial species in blood and CSF was Staphylococcus epidermidis. After S. epidermidis in blood samples, gram-negative isolates were frequently detected: Escherichia coli was the most frequent species, followed by Klebsiella pneumoniae and Enterobacter cloacae. Other frequently detected species were Serratia marcescens, Klebsiella aerogenes, Proteus mirabilis, Morganella morganii, and Salmonella spp. Among non-fermenters, the most frequent species were Pseudomonas aeruginosa, followed by Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia cepacia. Among gram-positive isolates, S. epidermidis was the most frequent species detected, followed by S. aureus.
In clinical isolates from CSF, gram-negative bacteria were frequently detected, with E. coli being the most prevalent, followed by K. pneumoniae and non-fermenters P. aeruginosa and A. baumannii. Again, S. epidermidis was the most frequent species detected among gram-positive bacteria, followed by S. aureus.
In clinical isolates from pleural fluid, the most frequent species detected among gram-negative bacteria was E. coli, followed by P. aeruginosa. Other species detected were K. pneumoniae, E. cloacae, P. mirabilis, and A. baumannii. In gram-positive isolates, S. aureus was the most frequently detected species.
Drug resistance of pathogens from blood
For pathogens recovered from blood, among Enterobacterales (except Salmonella species), carbapenem resistance ranged from 0% in K. aerogenes to 9.8% in K. pneumoniae. Quinolone resistance ranged from 0% to 35.8%, with higher percentages detected for ciprofloxacin than for levofloxacin, except in C. freundii and S. marcescens (Table 1A). The highest resistance was observed in E. coli (64% for ciprofloxacin and 57.8% for levofloxacin). In general, high resistance percentages were observed for cephalosporins, with lower values observed in E. cloacae.
E. coli | K. pneumoniae | K. aerogenes | E. cloacae | C. freundii | S. marcescens | P. mirabilis | M. morganii | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
AMP | 1602 | 87.2 | 0.2 | 12.6 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 52 | 44.2 | 0.0 | 55.8 | ND | ND | ND | ND |
FOX | 660 | 40.3 | 1.1 | 58.6 | 403 | 50.9 | 1 | 48.1 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 16 | 0.0 | 0.0 | 100 | ND | ND | ND | ND |
CXM | 884 | 68.3 | 0.7 | 31 | 641 | 69.1 | 0.5 | 30.4 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CTX | 655 | 74.2 | 0.2 | 25.6 | 557 | 71.1 | 0.0 | 28.9 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 32 | 43.8 | 0.0 | 56.2 | ND | ND | ND | ND |
CAZ | 1266 | 62.6 | 1.6 | 35.8 | 907 | 67.4 | 0.7 | 31.9 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 48 | 27.1 | 2.1 | 70.8 | ND | ND | ND | ND |
FEP | 2263 | 56 | 2.4 | 41.6 | 1380 | 58.5 | 2.8 | 38.7 | 80 | 6.2 | 0.0 | 93.8 | 509 | 5.7 | 3.7 | 90.6 | 55 | 13 | 0.0 | 87 | 217 | 2.8 | 3.7 | 93.5 | 79 | 25.3 | 1.3 | 73.4 | 22 | 0.0 | 0.0 | 100 |
ATM | 389 | 58.4 | 0.0 | 41.6 | 225 | 58.2 | 0.0 | 41.8 | 15 | 0.0 | 0.0 | 100 | 84 | 23.8 | 0.0 | 76.2 | ND | ND | ND | ND | 27 | 3.7 | 0 | 96.3 | ND | ND | ND | ND | ND | ND | ND | ND |
MEM | 2320 | 3.5 | 0.2 | 96.3 | 1382 | 9.8 | 0.4 | 89.8 | 80 | 0.0 | 0.0 | 100 | 501 | 3.4 | 0.2 | 96.4 | 54 | 3.7 | 0.0 | 96 | 210 | 5.7 | 0.5 | 93.8 | 81 | 1.2 | 0 | 98.8 | ND | ND | ND | ND |
IPM | 1587 | 3 | 0.7 | 96.3 | 816 | 12 | 0.1 | 87.9 | 52 | 0.0 | 7.7 | 92.3 | 293 | 4.1 | 4.1 | 91.8 | 35 | 2.9 | 11 | 86 | 46 | 8.7 | 8.7 | 82.6 | 23 | 56.5 | 34.8 | 8.7 | 10 | 10 | 0 | 90 |
SAM | 1636 | 49.9 | 23.2 | 26.9 | 1092 | 62 | 4.2 | 33.8 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 58 | 19 | 0 | 81 | ND | ND | ND | ND |
AMC | 395 | 27.1 | 13.4 | 59.5 | 203 | 34 | 14.8 | 51.2 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
TZP | 1722 | 12.4 | 5.7 | 81.9 | 906 | 20.1 | 11.4 | 68.5 | 63 | 30.2 | 6.3 | 63.5 | 329 | 14.6 | 3.3 | 82.1 | 39 | 5.1 | 5.1 | 90 | 44 | 6.8 | 6.8 | 86.4 | 47 | 0.0 | 2.1 | 97.9 | 19 | 0.0 | 0.0 | 100 |
AMK | 1187 | 3.5 | 0.3 | 96.2 | 965 | 8.1 | 1.1 | 90.8 | 53 | 1.9 | 0.0 | 98.1 | 367 | 4.1 | 0.3 | 95.6 | 39 | 5.1 | 0.0 | 95 | 151 | 9.9 | 0.7 | 89.4 | 46 | 2.2 | 4.3 | 93.5 | ND | ND | ND | ND |
GEN | 2346 | 39.9 | 1.2 | 58.9 | 1406 | 45.5 | 2.3 | 52.2 | 80 | 5 | 0.0 | 95 | 512 | 7.8 | 0.2 | 92 | 56 | 14 | 0.0 | 86 | 217 | 1.4 | 0.0 | 98.6 | 82 | 13.4 | 19.5 | 67.1 | 23 | 21.7 | 13 | 65.2 |
TOB | 198 | 39.4 | 15.7 | 44.9 | 199 | 54.8 | 8 | 37.2 | 14 | 0.0 | 0.0 | 100 | 58 | 12.1 | 1.7 | 86.2 | ND | ND | ND | ND | 20 | 0.0 | 0.0 | 100 | ND | ND | ND | ND | ND | ND | ND | ND |
CIP | 2358 | 64 | 2.2 | 33.8 | 1395 | 25.3 | 17.1 | 57.6 | 80 | 3.8 | 2.5 | 93.7 | 510 | 5.1 | 2 | 92.9 | 55 | 9.1 | 3.6 | 87 | 217 | 1.4 | 0.9 | 97.7 | 81 | 35.8 | 3.7 | 60.5 | 23 | 30.4 | 13 | 56.5 |
LVX | 735 | 57.8 | 0.8 | 41.4 | 347 | 11.2 | 2.3 | 86.5 | 19 | 0.0 | 0.0 | 100 | 134 | 3.7 | 1.5 | 94.8 | 20 | 15 | 0.0 | 85 | 41 | 2.4 | 4.9 | 92.7 | 12 | 16.7 | 16.7 | 66.6 | ND | ND | ND | ND |
SXT | 1596 | 62.3 | 0.1 | 37.6 | 979 | 59.8 | 0.0 | 40.2 | 47 | 4.3 | 0.0 | 95.7 | 361 | 15.5 | 0.0 | 84.5 | 41 | 27 | 0.0 | 73 | 169 | 8.9 | 0.0 | 91.1 | 54 | 40.7 | 0.0 | 59.3 | 14 | 57.1 | 0.0 | 42.9 |
Salmonella spp. | S. Typhi | A. baumannii | P. aeruginosa | S. maltophilia | B. cepacia | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
AMP | 70 | 32.9 | 0.0 | 67.1 | 65 | 0 | 0 | 100 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CXM | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CTX | 23 | 4.3 | 0.0 | 95.7 | 63 | 0.0 | 0.0 | 100 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CAZ | 69 | 1.4 | 0.0 | 98.6 | 69 | 0.0 | 0.0 | 100 | 557 | 74.7 | 3.9 | 21.4 | ND | ND | ND | ND | ND | ND | ND | ND | 42 | 0.0 | 11.9 | 88.1 |
FEP | 64 | 0.0 | 4.7 | 95.3 | 66 | 0.0 | 0.0 | 100 | 642 | 71.8 | 0.9 | 27.3 | 906 | 21.3 | 5.7 | 73 | ND | ND | ND | ND | ND | ND | ND | ND |
ATM | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 109 | 21.1 | 2.8 | 76.1 | ND | ND | ND | ND | ND | ND | ND | ND |
MEM | ND | ND | ND | ND | ND | ND | ND | ND | 729 | 72.6 | 0.4 | 27 | 893 | 30 | 5.4 | 64.6 | ND | ND | ND | ND | 60 | 5.0 | 1.7 | 93.3 |
IPM | ND | ND | ND | ND | ND | ND | ND | ND | 386 | 79.5 | 0.3 | 20.2 | 590 | 36.1 | 1.7 | 62.2 | ND | ND | ND | ND | ND | ND | ND | ND |
SAM | ND | ND | ND | ND | ND | ND | ND | ND | 663 | 59.9 | 13.6 | 26.5 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
TZP | ND | ND | ND | ND | ND | ND | ND | ND | 455 | 84.8 | 0.4 | 14.8 | 642 | 22.6 | 9 | 68.4 | ND | ND | ND | ND | ND | ND | ND | ND |
AMK | ND | ND | ND | ND | ND | ND | ND | ND | 125 | 58.4 | 9.6 | 32 | 576 | 13.7 | 3.5 | 82.8 | ND | ND | ND | ND | ND | ND | ND | ND |
GEN | ND | ND | ND | ND | ND | ND | ND | ND | 736 | 55.8 | 11.3 | 32.9 | 900 | 15.1 | 5 | 79.9 | ND | ND | ND | ND | ND | ND | ND | ND |
TOB | ND | ND | ND | ND | ND | ND | ND | ND | 118 | 69.5 | 11 | 19.5 | 80 | 25 | 0.0 | 75 | ND | ND | ND | ND | ND | ND | ND | ND |
CIP | 88 | 11.4 | 9.1 | 31.8 | 65 | 11 | 0 | 91 | 730 | 73.4 | 0.1 | 26.5 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
LVX | ND | ND | ND | ND | ND | ND | ND | ND | 146 | 62.3 | 1.4 | 36.3 | ND | ND | ND | ND | 110 | 3.6 | 6.4 | 90 | ND | ND | ND | ND |
SXT | 70 | 25.7 | 0.0 | 74.3 | 65 | 0.0 | 0.0 | 100 | 441 | 63.3 | 0.0 | 36.7 | ND | ND | ND | ND | 313 | 9.3 | 0.3 | 90.4 | 39 | 20.5 | 0.0 | 79.5 |
Notes:
- AMP
-
ampicillin
- FOX
-
cefoxitin
- CXM
-
cefuroxime
- CTX
-
cefotaxime
- CAZ
-
ceftazidime
- FEP
-
cefepime
- ATM
-
aztreonam
- MEM
-
meropenem
- IPM
-
imipenem
- SAM
-
ampicillin/sulbactam
- TZP
-
piperacillin/tazobactam
- AMK
-
amikacin
- GEN
-
gentamicin
- TOB
-
tobramycin
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- SXT
-
trimethoprim-sulfamethoxazole
- ND
-
not determined
A high susceptibility was observed for Salmonella enterica serovar Typhi (S. Typhi) strains, with resistance detected for ciprofloxacin (11%). Concerning non-fermenters, more than 60% of A. baumannii were resistant to most antibiotics tested; the highest resistance observed in P. aeruginosa was for imipenem (36.1%). In B. cepacia, the lowest resistance rate was detected for ceftazidime (0%) (Table 1B).
Among gram-positive isolates, almost 30% of S. aureus strains were methicillin-resistant, and 19% of E. faecium were vancomycin-resistant. Results from more than 50 strains were obtained for S. pneumoniae, with the highest percentage of resistance detected for trimethoprim-sulfamethoxazole (42.1%; Table 2). Compared with the BMD method, similar resistance percentages were observed for levofloxacin, erythromycin, and vancomycin. However, values observed for chloramphenicol and trimethoprim/sulfamethoxazole were higher using the BMD method than routine, conventional methods. There was a discrepancy in resistance to penicillin and cefotaxime that could not be explained; perhaps it is associated with a limited number of strains with conventional routine methods.
S. aureus | S. epidermidis | E. faecalis | E. faecium | S. pneumoniaea | S. pneumoniaeb | Streptococcus spp. viridans group | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
PEN | 353 | 90.4 | 0.0 | 9.6 | 576 | 94.8 | 0.0 | 5.2 | 127 | 15.7 | 0.0 | 84.3 | 55 | 78.2 | 0.0 | 21.8 | 13 | 23.1 | 30.8 | 46.2 | 49 | 12.2 | 14.3 | 73.5 | 26 | 3.8 | 7.7 | 88.5 |
AMP | ND | ND | ND | ND | ND | ND | ND | ND | 589 | 1.5 | 0.0 | 98.5 | 247 | 64 | 0.0 | 36 | ND | ND | ND | ND | ND | ND | ND | ND | 25 | 8 | 0.0 | 92 |
OXA | 1250 | 27.1 | 0.0 | 72.9 | 2899 | 82.7 | 0.0 | 17.3 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | 656 | 29.9 | 0.0 | 70.1 | 1980 | 85.5 | 0.0 | 14.5 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CTX | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 27 | 14.8 | 3.7 | 81.5 | 49 | 16.3 | 20.4 | 63.3 | ND | ND | ND | ND |
FEP | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 26 | 3.8 | 0 | 96.2 |
CIP | 1222 | 26.8 | 1.1 | 72.1 | 2910 | 61.8 | 4.4 | 33.8 | 526 | 31.9 | 4 | 64.1 | 220 | 47.7 | 20.5 | 31.8 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
LVX | 903 | 25.9 | 0.7 | 73.4 | 2399 | 67.5 | 0.5 | 32 | 461 | 28.9 | 0.4 | 70.7 | 187 | 44.4 | 11.2 | 44.4 | 58 | 1.7 | 1.7 | 96.6 | 49 | 2.0 | 2.0 | 96.0 | ND | ND | ND | ND |
ERY | 1260 | 32.1 | 0.7 | 67.2 | 2852 | 80.8 | 0.6 | 18.7 | 539 | 59 | 28.4 | 12.6 | 220 | 76.8 | 19.5 | 3.6 | 55 | 34.5 | 0 | 65.5 | 49 | 44.9 | 0.0 | 55.1 | ND | ND | ND | ND |
CLI | 1230 | 31.3 | 0.2 | 68.5 | 2790 | 72.1 | 0.7 | 27.2 | ND | ND | ND | ND | ND | ND | ND | ND | 56 | 23.2 | 10.7 | 66.1 | ND | ND | ND | ND | ND | ND | ND | ND |
TET | 977 | 3.2 | 0.1 | 96.7 | 2393 | 11.9 | 0.3 | 87.8 | 438 | 75.3 | 0 | 24.7 | 170 | 61.8 | 0 | 38.2 | 51 | 23.5 | 9.8 | 66.7 | ND | ND | ND | ND | ND | ND | ND | ND |
GEN | 1224 | 8.9 | 3 | 88.1 | 2932 | 41.4 | 11.6 | 47 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SXT | 1286 | 4.1 | 0.0 | 95.9 | 2926 | 57.2 | 0.0 | 42.8 | ND | ND | ND | ND | ND | ND | ND | ND | 57 | 42.1 | 8.8 | 49.1 | 49 | 57.1 | 14.3 | 28.6 | ND | ND | ND | ND |
LZD | 1255 | 0.2 | 0.0 | 99.8 | 2815 | 4.6 | 0.0 | 95.4 | 584 | 3.4 | 4.3 | 92.3 | 242 | 2.9 | 1.2 | 95.9 | 36 | 0.0 | 0.0 | 100 | ND | ND | ND | ND | ND | ND | ND | ND |
RIF | 809 | 3.2 | 0.1 | 96.7 | 2211 | 10.8 | 0.0 | 1.4 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CHL | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 29 | 6.9 | 0.0 | 93.1 | 49 | 36.7 | 0.0 | 63.3 | ND | ND | ND | ND |
VAN | 1285 | 0.0 | 0.0 | 100 | 3002 | 0.0 | 0.0 | 100 | 588 | 2 | 0.0 | 98 | 247 | 19 | 0.0 | 81 | 58 | 0.0 | 0.0 | 100 | 49 | 0.0 | 0.0 | 100.0 | 26 | 0.0 | 0.0 | 100 |
Notes:
- PEN
-
penicillin
- AMP
-
ampicillin
- OXA
-
oxacillin
- FOX
-
cefoxitin
- CTX
-
cefotaxime
- FEP
-
cefepime
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- ERY
-
erythromycin
- CLI
-
clindamycin
- TET
-
tetracycline
- GEN
-
gentamicin
- SXT
-
trimethoprim-sulfamethoxazole
- LZD
-
linezolid
- RIF
-
rifampicin
- CHL
-
chloramphenicol
- VAN
-
vancomycin
- ND
-
not determined
Drug resistance of pathogens from cerebrospinal fluid
For pathogens recovered from CSF, carbapenem resistance was as high as 71.4% in A. baumannii. Resistance rates higher than 44% for gentamicin and 61% for cephalosporins were detected in E. coli and K. pneumoniae. E. coli exhibited more than 60% resistance to quinolones. In A. baumannii, the resistance rates of most evaluated antibiotics were higher than 60% (Table 3). Among E. coli (n = 91), 86.9% showed to be extended-spectrum beta-lactamase producers; among K. pneumoniae (n = 39), 71.8%. Among gram-positive isolates, 44.4% of S. aureus showed resistance to methicillin, and 36.4% of E. faecium were resistant to vancomycin (Table 4).
E. coli | K. pneumoniae | S. marcescens | E. cloacae | P. aeruginosa | A. baumannii | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
AMP | 112 | 94.6 | 0.0 | 5.4 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | 24 | 66.7 | 0.0 | 33.3 | 14 | 21.4 | 7.1 | 71.5 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CXM | 63 | 81 | 0.0 | 19 | 50 | 80 | 0.0 | 20 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CTX | 60 | 78.3 | 0.0 | 21.7 | 37 | 75.7 | 0.0 | 24.3 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 17 | 88.2 | 0.0 | 11.8 |
CAZ | 76 | 75 | 0.0 | 25 | 48 | 75 | 0.0 | 25 | ND | ND | ND | ND | ND | ND | ND | ND | 49 | 6.1 | 6.1 | 87.8 | 34 | 85.3 | 0.0 | 14.7 |
FEP | 131 | 74 | 6.1 | 19.9 | 68 | 61.8 | 14.7 | 23.5 | 35 | 0.0 | 0.0 | 100 | 16 | 0 | 6.2 | 93.8 | 73 | 6.8 | 16.4 | 76.8 | 54 | 72.2 | 9.3 | 18.5 |
ATM | 42 | 95.2 | 0.0 | 4.8 | 17 | 88.2 | 0.0 | 11.8 | 21 | 66.7 | 0.0 | 33.3 | ND | ND | ND | ND | 10 | 30 | 0 | 70 | ND | ND | ND | ND |
MEM | 124 | 1.6 | 0.0 | 98.4 | 61 | 4.9 | 1.6 | 93.5 | 25 | 0.0 | 4 | 96 | 16 | 0 | 0 | 100 | 67 | 31.3 | 16.4 | 52.3 | 49 | 71.4 | 2 | 26.6 |
IPM | 49 | 2 | 0.0 | 98 | 33 | 6.1 | 0.0 | 93.9 | 25 | 8 | 16 | 76 | ND | ND | ND | ND | 43 | 55.8 | 9.3 | 34.9 | 30 | 56.7 | 6.7 | 36.6 |
SAM | 116 | 63.8 | 19.8 | 16.4 | 52 | 73.1 | 1.9 | 25 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 50 | 50 | 16 | 34 |
AMC | 17 | 52.9 | 17.6 | 29.5 | 17 | 58.8 | 5.9 | 35.3 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
TZP | 78 | 3.8 | 6.4 | 89.8 | 34 | 8.8 | 29.4 | 61.8 | 25 | 56 | 0.0 | 44 | ND | ND | ND | ND | 53 | 9.4 | 7.5 | 83.1 | 37 | 62.2 | 2.7 | 35.1 |
AMK | 105 | 1.9 | 0.0 | 98.1 | 49 | 14.3 | 0.0 | 85.7 | 13 | 0.0 | 0.0 | 100 | 11 | 0.0 | 0.0 | 100 | 55 | 7.3 | 5.5 | 87.2 | ND | ND | ND | ND |
GEN | 131 | 49.6 | 1.5 | 48.9 | 69 | 44.9 | 0.0 | 55.1 | 35 | 5.7 | 5.7 | 88.6 | 16 | 6.2 | 0.0 | 93.8 | 72 | 5.6 | 22.2 | 72.2 | 54 | 68.5 | 9.3 | 22.2 |
TOB | 38 | 34.2 | 52.6 | 13.2 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 10 | 0.0 | 0.0 | 100 | ND | ND | ND | ND |
CIP | 119 | 71.4 | 0.0 | 28.6 | 55 | 29.1 | 5.5 | 65.4 | 15 | 0.0 | 0.0 | 100 | 15 | 0.0 | 0.0 | 100 | 61 | 3.3 | 8.2 | 88.5 | 43 | 83.7 | 0 | 16.3 |
LVX | 23 | 60.9 | 0.0 | 39.1 | 14 | 7.1 | 0.0 | 92.9 | ND | ND | ND | ND | ND | ND | ND | ND | 10 | 0 | 40 | 60 | ND | ND | ND | ND |
SXT | 116 | 58.6 | 0.0 | 41.4 | 64 | 59.4 | 0.0 | 40.6 | 30 | 6.7 | 0.0 | 93.3 | 12 | 8.3 | 0.0 | 91.7 | ND | ND | ND | ND | 36 | 61.1 | 0.0 | 38.9 |
Notes:
- AMP
-
ampicillin
- FOX
-
cefoxitin
- CXM
-
cefuroxime
- CTX
-
cefotaxime
- CAZ
-
ceftazidime
- FEP
-
cefepime
- ATM
-
aztreonam
- MEM
-
meropenem
- IPM
-
imipenem
- SAM
-
ampicillin/sulbactam
- AMC
-
amoxicillin/clavulanate
- TZP
-
piperacillin/tazobactam
- AMK
-
amikacin
- GEN
-
gentamicin
- TOB
-
tobramycin
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- SXT
-
trimethoprim-sulfamethoxazole
- ND
-
not determined
S. aureus | S. epidermidis | E. faecium | E. faecalis | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
PEN | 19 | 73.7 | 0.0 | 26.3 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
AMP | 16 | 81.2 | 0.0 | 18.8 | ND | ND | ND | ND | 11 | 63.6 | 0.0 | 36.4 | 22 | 0.0 | 0.0 | 100 |
OXA | 68 | 35.3 | 0.0 | 64.7 | 224 | 75 | 0.0 | 25 | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | 45 | 44.4 | 0.0 | 55.6 | 139 | 77.7 | 0.0 | 22.3 | ND | ND | ND | ND | ND | ND | ND | ND |
CIP | 59 | 32.2 | 3.4 | 64.4 | 219 | 43.8 | 8.2 | 48 | 10 | 60 | 10 | 30 | 15 | 26.7 | 6.7 | 66.6 |
LVX | 49 | 34.7 | 0.0 | 65.3 | 187 | 50.3 | 0.0 | 49.7 | ND | ND | ND | ND | 15 | 26.7 | 0 | 73.3 |
ERY | 60 | 43.3 | 0.0 | 56.7 | 208 | 70.2 | 1 | 28.8 | 10 | 90 | 0.0 | 10 | 15 | 33.3 | 46.7 | 20 |
CLI | 59 | 47.5 | 0.0 | 52.5 | 208 | 53.4 | 1 | 45.6 | ND | ND | ND | ND | ND | ND | ND | ND |
TET | 49 | 2 | 0.0 | 98 | 187 | 9.1 | 0.5 | 90.4 | ND | ND | ND | ND | 15 | 73.3 | 0.0 | 26.7 |
GEN | 63 | 11.1 | 3.2 | 85.7 | 232 | 33.6 | 11.6 | 54.8 | ND | ND | ND | ND | ND | ND | ND | ND |
SXT | 65 | 0 | 0.0 | 100 | 233 | 42.9 | 0.0 | 57.1 | ND | ND | ND | ND | ND | ND | ND | ND |
RIF | 56 | 7.1 | 0.0 | 92.9 | 168 | 10.7 | 0.6 | 88.7 | ND | ND | ND | ND | ND | ND | ND | ND |
LZD | 66 | 0.0 | 0.0 | 100 | 214 | 3.7 | 0.0 | 96.3 | 11 | 0.0 | 0.0 | 100 | 28 | 3.6 | 3.6 | 92.8 |
VAN | 70 | 0.0 | 0.0 | 100 | 224 | 0.4 | 0.4 | 99.2 | 11 | 36.4 | 0.0 | 63.6 | 29 | 3.4 | 13.8 | 82.8 |
Notes:
- PEN
-
penicillin
- AMP
-
ampicillin
- OXA
-
oxacillin
- FOX
-
cefoxitin
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- ERY
-
erythromycin
- CLI
-
clindamycin
- TET
-
tetracycline
- GEN
-
gentamicin
- SXT
-
trimethoprim-sulfamethoxazole
- RIF
-
rifampicin
- LZD
-
linezolid
- VAN
-
vancomycin
- ND
-
not determined
Drug resistance of pathogens from pleural fluid
For pathogens recovered from pleural fluid, among gram-negative isolates, carbapenem resistance was as high as 96.3% in A. baumannii. Levofloxacin resistance was as high as 100% in A. baumannii and 87% in E. coli (Table 5). Resistance to third-generation cephalosporins was more than 68% in E. coli and K. pneumoniae. Moreover, 54% of E. coli (n = 85) and 60% of K. pneumoniae (n = 45) were shown to be extended-spectrum beta-lactamase producers. Among gram-positive isolates, methicillin resistance for S. aureus was almost 35%, and vancomycin resistance for E. faecium was 27.6% (Table 6).
E. coli | K. pneumoniae | E. cloacae | P. mirabilis | A. baumannii | P. aeruginosa | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
AMP | 94 | 86 | 1.1 | 12.8 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | 35 | 40 | 2.9 | 57.1 | 10 | 20 | 0.0 | 80 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
CXM | 67 | 76 | 0.0 | 23.9 | 34 | 82 | 0.0 | 72 | ND | ND | ND | ND | 10 | 60 | 0.0 | 40 | ND | ND | ND | ND | ND | ND | ND | ND |
CTX | 66 | 76 | 0.0 | 24.2 | 33 | 82 | 0.0 | 41 | ND | ND | ND | ND | 10 | 60 | 0.0 | 40 | 27 | 33.3 | 18.5 | 48.2 | ND | ND | ND | ND |
CAZ | 95 | 76 | 1.1 | 23.2 | 45 | 69 | 0.0 | 31 | ND | ND | ND | ND | 11 | 54.5 | 0.0 | 45.5 | 52 | 59.6 | 7.7 | 32.7 | 81 | 18.5 | 7.4 | 74.1 |
FEP | 125 | 66 | 0.8 | 32.8 | 58 | 62 | 0.0 | 38 | 44 | 20.5 | 6.8 | 72.7 | 13 | 46.2 | 0.0 | 53.8 | 58 | 63.8 | 1.7 | 34.5 | 98 | 21.4 | 6.1 | 72.5 |
MEM | 125 | 4 | 0.0 | 96 | 59 | 12 | 0.0 | 49 | 44 | 11.4 | 0.0 | 88.6 | 13 | 0.0 | 0.0 | 100 | 58 | 56.9 | 5.2 | 37.9 | 97 | 39.2 | 11.3 | 49.5 |
IPM | 57 | 7 | 1.8 | 91.2 | 20 | 5 | 0.0 | 46 | 12 | 0 | 0.0 | 100 | ND | ND | ND | ND | 27 | 96.3 | 3.7 | 0.0 | 41 | 68.3 | 2.4 | 29.3 |
SAM | 113 | 62 | 16 | 22.2 | 53 | 72 | 0.0 | 28 | ND | ND | ND | ND | 13 | 15.4 | 7.7 | 76.9 | 56 | 55.4 | 8.9 | 35.7 | ND | ND | ND | ND |
TZP | 62 | 18 | 4.8 | 77.5 | 25 | 8 | 20 | 20 | 13 | 23.1 | 15.4 | 61.5 | ND | ND | ND | ND | 31 | 100 | 0.0 | 0.0 | 40 | 20 | 12.5 | 67.5 |
AMK | 100 | 0 | 0 | 100 | 50 | 10 | 2 | 88 | 37 | 18.9 | 2.7 | 78.4 | 12 | 8.3 | 25 | 66.7 | 11 | 90.9 | 0.0 | 9.1 | 83 | 16.9 | 2.4 | 80.7 |
GEN | 126 | 40 | 0.8 | 59.5 | 59 | 54 | 0.0 | 88 | 44 | 11.4 | 4.5 | 84.1 | 13 | 7.7 | 53.8 | 38.5 | 59 | 57.6 | 8.5 | 33.9 | 97 | 20.6 | 3.1 | 76.3 |
CIP | 125 | 66 | 2.4 | 31.2 | 59 | 37 | 22 | 40.7 | 42 | 23.8 | 0.0 | 76.2 | 13 | 38.5 | 15.4 | 46.2 | 58 | 67.2 | 0.0 | 32.8 | 97 | 24.7 | 6.2 | 69.1 |
LVX | 23 | 87 | 0.0 | 13 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 11 | 100 | 0.0 | 0.0 | 13 | 30.8 | 7.7 | 61.5 |
TGC | 16 | 0.0 | 0.0 | 100 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SXT | 95 | 60 | 0.0 | 40 | 45 | 78 | 0 | 18 | 36 | 27.8 | 0.0 | 72.2 | 11 | 72.7 | 0 | 27.3 | 40 | 52.5 | 0.0 | 47.5 | ND | ND | ND | ND |
Notes:
- AMP
-
ampicillin
- FOX
-
cefoxitin
- CXM
-
cefuroxime
- CTX
-
cefotaxime
- CAZ
-
ceftazidime
- FEP
-
cefepime
- MEM
-
meropenem
- IPM
-
imipenem
- SAM
-
ampicillin/sulbactam
- TZP
-
piperacillin/tazobactam
- AMK
-
amikacin
- GEN
-
gentamicin
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- TGC
-
tigecycline
- SXT
-
trimethoprim-sulfamethoxazole
- ND
-
not determined
S. aureus | E. faecalis | E. faecium | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic | n | %R | %I | %S | n | %R | %I | %S | n | %R | %I | %S |
PEN | 18 | 94.4 | 0.0 | 5.6 | 17 | 5.9 | 0.0 | 94.1 | ND | ND | ND | ND |
AMP | 14 | 92.9 | 0.0 | 7.1 | 60 | 0 | 0.0 | 100 | 29 | 86.2 | 0 | 13.8 |
OXA | 105 | 31.4 | 0.0 | 68.6 | ND | ND | ND | ND | ND | ND | ND | ND |
FOX | 75 | 34.7 | 0.0 | 65.3 | 13 | 100 | 0.0 | 0.0 | ND | ND | ND | ND |
CIP | 105 | 30.5 | 1 | 68.6 | 59 | 37.3 | 6.8 | 55.9 | 29 | 51.7 | 27.6 | 20.7 |
LVX | 88 | 31.8 | 0 | 68.2 | 44 | 34.1 | 0.0 | 65.9 | 24 | 45.8 | 4.2 | 50 |
ERY | 105 | 37.1 | 1.9 | 61 | 59 | 57.6 | 32.2 | 10.2 | 29 | 96.6 | 3.4 | 0.0 |
CLI | 105 | 34.3 | 0.0 | 65.7 | 15 | 100 | 0.0 | 0 | ND | ND | ND | ND |
TET | 90 | 8.9 | 0.0 | 91.1 | 45 | 73.3 | 0.0 | 26.7 | 23 | 52.2 | 0.0 | 47.8 |
GEN | 105 | 12.4 | 5.7 | 81.9 | 13 | 100 | 0.0 | 0.0 | ND | ND | ND | ND |
SXT | 106 | 2.8 | 0.0 | 97.2 | 14 | 92.9 | 0.0 | 7.1 | ND | ND | ND | ND |
RIF | 83 | 2.4 | 0.0 | 97.6 | ND | ND | ND | ND | ND | ND | ND | ND |
LZD | 107 | 1.9 | 0.0 | 98.1 | 60 | 0.0 | 3.3 | 96.7 | 28 | 0.0 | 0.0 | 100 |
TGC | 12 | 0 | 0.0 | 100 | 11 | 0.0 | 0.0 | 100 | 9 | 0.0 | 0.0 | 100 |
VAN | 105 | 1.9 | 0.0 | 98.1 | 59 | 3.4 | 0.0 | 96.6 | 29 | 27.6 | 0.0 | 72.4 |
CHL | ND | ND | ND | ND | 13 | 15.4 | 0.0 | 84.6 | ND | ND | ND | ND |
Notes:
- PEN
-
penicillin
- AMP
-
ampicillin
- OXA
-
oxacillin
- FOX
-
cefoxitin
- CIP
-
ciprofloxacin
- LVX
-
levofloxacin
- ERY
-
erythromycin
- CLI
-
clindamycin
- TET
-
tetracycline
- GEN
-
gentamicin
- SXT
-
trimethoprim-sulfamethoxazole
- RIF
-
rifampicin
- LZD
-
linezolid
- TGC
-
tigecycline
- VAN
-
vancomycin
- CHL
-
chloramphenicol
- ND
-
not determined
Discussion
In the present study, most bacterial species detected were gram-negative (when no S. epidermidis was included), with E. coli being the most frequent bacterial species detected in blood, CSF, and pleural fluid.
Regarding blood cultures, our results are similar to those reported in an Austrian study from 2006 to 2015 in which E. coli was the most common isolated pathogen (n = 2,869), followed by S. aureus (n = 1,439), Enterococcus spp. (n = 953), and Klebsiella spp. (n = 816) (Kreidl et al., 2019). Furthermore, a study in a seven-year North American study in which 24,179 cases of bloodstream infections were included, the most common organisms were coagulase-negative staphylococci (31% of isolates), followed by S. aureus (20%) and Enterococci (9%) (Wisplinghoff et al., 2004).
In our study, the most frequent species was E. coli (when no S. epidermidis was considered). It has been reported that this bacterial species is responsible for 48 per 100,000 person-years cases of bacteremia, increasing to 100 per 100,000 person-years in the 55–75 age group and over 300 per 100,000 person-years in the 75–85 age group (Bonten et al., 2021). These data underline the relevance of this bacterial species.
Commercial products dominate antimicrobial susceptibility testing methods in hospital laboratories, with relatively high accuracy. These methods have become better suited to fastidious species like S. pneumoniae, for which the need for red blood cells complicates the use of BMD. Compared with the BMD method, the proportion of penicillin-resistant S. pneumoniae was reported more frequently when routine, conventional methods were used. This was not observed for levofloxacin, erythromycin, trimethoprim-sulfamethoxazole, and vancomycin. A slight decrease in penicillin and cefotaxime resistance was observed in this study period compared to the previous decade, 2009–2018 (Garza-González et al., 2020), which might explain the continued use of pneumococcal conjugate vaccines since 2008. An increase in erythromycin resistance was observed, and a further increase is likely to be expected shortly, considering the use of azithromycin as an inflammatory aid in COVID-19 patients.
In blood cultures, the possibility of contamination must always be considered in interpreting positive results because microbes that are not in the bloodstream may be introduced into the bottle during blood collection (Gonsalves et al., 2009). Contamination is often due to organisms that can be part of the skin microbiota, such as S. epidermidis. In our study, the most frequent species detected was S. epidermidis, and according to our results, contamination seems excessive and points to the need for improving blood intake procedures. However, other pathogens detected in this study are not frequently observed in the skin (e.g., E. coli, K. pneumoniae. E. cloacae, S. marcescens, K. aerogenes, and P. mirabilis). Thus, they are most probably from the clinical specimen. A small sample volume is associated with difficulties in maintaining sterile conditions due to poor venous access (Gonsalves et al., 2009; Bekeris et al., 2005); thus, the contamination rate inversely correlates with blood volume (Gonsalves et al., 2009; Bekeris et al., 2005). Additionally, venipuncture, arterial access, or central venous access are associated with different contamination rates: 36%, 10%, and 7%, respectively (Gonsalves et al., 2009). Our study has no such data to verify these values, but laboratories followed the manufacturer’s recommendations regarding volume in general.
In this study, the drug resistance of pathogens from blood was similar to our previous reports (Garza-González et al., 2021; Garza-González et al., 2020; Garza-González et al., 2019). This study added data on drug susceptibility for Citrobacter freundii, Serratia marcescens, Proteus mirabilis, Morganella morganii, and Burkholderia cepacia, for which limited information is available in Mexico.
Regarding S. Typhi, the widespread use of fluoroquinolones has led to the emergence of decreased ciprofloxacin susceptibility. Our previous report, with only 10 clinical isolates included, showed 20% resistance (Garza-González et al., 2019). This work detected an 11% resistance (with 88 clinical isolates included).
Regarding the B. cepacia, trimethoprim-sulfamethoxazole remains a recommended first-line therapy (Avgeri et al., 2009). Our report detected 20.5% resistance for this drug; another first-line therapy, meropenem, showed a resistance of 5%. The primary alternative therapeutic agents beyond trimethoprim-sulfamethoxazole include ceftazidime and meropenem (Avgeri et al., 2009). This study showed that the high susceptibility to ceftazidime (0% resistance, at least in vitro) renders this antibiotic a good alternative in the studied populations.
The bacterial pathogens detected in CSF are various according to age. Between 16 and 50 years, Neisseria meningitidis and S. pneumoniae are frequently reported. In those over 50 years, Listeria monocytogenes and aerobic gram-negative bacilli are encountered (van deBeek et al., 2016). Furthermore, in immunocompromised individuals over 50 years of age, aerobic gram-negative bacilli and Salmonella spp. are frequently found (van deBeek et al., 2016). Other gram-negative bacteria and P. aeruginosa are pathogens found after neurosurgery or head trauma (Tunkel et al., 2017). Regardless of age, the most frequent causative agents isolated from CSF have been reported to be gram-negative bacteria, with A. baumannii, K. pneumoniae, and E. coli as the most frequently recovered species (Hu et al., 2019). In our study, similar results were observed, with E. coli being the most prevalent, if we omitted S. epidermidis.
S. epidermidis may have relevance in patients with hydrocephalus controlled by diverting or shunting the fluid around the obstruction and into a suitable body cavity. Shunts may be colonized primarily by skin organisms, with S. epidermidis being the most common cause of shunt colonization (Yakut et al., 2018; Bayston, 1989). In our population, S. epidermidis was the most frequent bacterial species detected. Whether this organism was associated with shunt infections needs further exploration.
In China, 244,843 strains from 44 teaching hospitals were analyzed in 2018 (14.8% from blood and 1.3% from CSF). In CSF only, 64.1% of K. pneumoniae and 60% of P. aeruginosa were resistant to carbapenem (29). Fortunately, we detected much lower percentages of resistance (4.9% and 31.3%). These data support the need to monitor drug resistance in specific populations.
Aerobic organisms are most implicated in pleural infection. When all populations are considered, streptococcal species are the primary cause at approximately 60%, followed by staphylococcal species and Enterococcus (Davies et al., 2010). The gram-negative aerobes cause about 15% and anaerobes nearly 14% of identified pathogens (Davies et al., 2010).
When causative agents are stratified, causative agents vary considerably by the site of acquisition, age, or comorbidities. For example, 50% of cases of community-acquired empyema are due to streptococci, and the remainder is due to staphylococci, anaerobes, and gram-negative bacilli (Maskell et al., 2005). However, in hospital-acquired empyema (associated with hospital-acquired pneumonia) or iatrogenic causes, staphylococci, gram-negative bacilli, Enterococcus species, and cefoxitin-resistant S. aureus are the most frequently implicated organisms. In pediatric patients, the most frequent isolate in pleural fluids reported is S. pneumoniae (up to 48%), followed by group A Streptococcus, S. aureus. In patients with comorbidities, especially diabetes or alcoholism, gram-negative bacteria are the most frequent (Maskell et al., 2005). In our study, E. coli and S. aureus were most frequently detected, with a significant role of P. aeruginosa as the causative agent. Unfortunately, we have no data on the comorbidities associated with these infections.
The selection of appropriate empiric therapy results in better outcomes in severe infections occurring in sterile fluids, i.e., blood, cerebrospinal and pleural fluids. The prevalent, most frequently isolated antibiotic-resistant pathogens in every hospital should guide the initial therapy selection. Also helpful is the knowledge of previous experiences of discordant therapy in bacteremia caused by frequent resistant pathogens like S. aureus or Enterobacteriaceae. Adjustments should be made according to the report on cultures and susceptibility (Kadri et al., 2018; Kadri et al., 2021). The results from this and other studies from the INVIFAR network will help in selecting the appropriate empiric therapy.
Part of the isolates was reported in a previous manuscript of the network, specifically, those collected from the second semester of 2019 and the second semester of 2020 (López-Jácome et al., 2021), exclusively from the centers that participated in both studies and from blood isolates.
In this study, each laboratory identified the strains and tested their susceptibilities using routine, conventional methods, including commercial microdilution systems. Each system has advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards used (Gajic et al., 2022).
Some studies have evaluated the performance of these instruments. For example, a multicenter evaluation showed that categorical agreement between the Phoenix system and the broth microdilution method for 2013 streptococcal isolates, including S. pneumoniae, ranged from 92% to 100% (Richter et al., 2007). Furthermore, the performance of the Phoenix, Vitek 2, and the MicroScan have been compared with the microdilution broth reference method for 311 clinical isolates of S. pneumoniae, and the overall essential agreement between each test was >95% (Mittman et al., 2009). Additionally, 109 S. maltophilia bloodstream isolates were analyzed, and very major errors were >.3% for trimethoprim-sulfamethoxazole (MicroScan, Phoenix), levofloxacin (MicroScan), and ceftazidime (all systems).
Limitations of this retrospective study are worth noting. First, we were unable to collect complete data on the age of the patients. Second, no clinical data were available to support the indication of the study or the relevance of the clinical isolate. Third, our results represent the combined data of general, mother and child, specialty hospitals, and other centers; thus, each hospital needs to address its results. Fourth, not all antibiotics were available from all centers; thus, some antibiotics are not included, such as levofloxacin for P. aeruginosa. Fifth, different methodologies were used for the detection of antibiotic susceptibility.
Conclusions
The results presented in this article represent the consolidated analysis of isolates from 45 centers. S. epidermidis was the most frequently recovered bacterial species from blood and CSF. Whether these isolates represent contamination or are associated with infection remains unclear. Gram-negative bacteria, with E. coli most prevalent, are frequently recovered from CSF, blood, and pleural fluid. In S. pneumoniae, the routine, conventional methods can help detect resistance percentages for levofloxacin, cefotaxime, and vancomycin.